RECRUITING

Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias. The investigators aim to study: 1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy. Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.

Official Title

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Quick Facts

Study Start:2023-12-13
Study Completion:2029-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06575881

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults aged 18 and older
  2. * Diagnosed with AF, frequent PVCs, or VT before age 60
  3. * Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation
  4. * Able to provide written, informed consent
  5. * P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.
  1. * Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure
  2. * VUS in 'possibly pathogenic' subgroup (control group only)
  3. * Previous PVC or VT ablation
  4. * LVEF \<20%
  5. * Prosthetic mitral or aortic valve
  6. * Contraindication to heparin
  7. * Prior myocardial infarction

Contacts and Locations

Study Contact

Dakota Graherr, RN
CONTACT
615-936-6069
dakota.grauherr@vumc.org

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-13
Study Completion Date2029-12

Study Record Updates

Study Start Date2023-12-13
Study Completion Date2029-12

Terms related to this study

Additional Relevant MeSH Terms

  • Atrial Fibrillation
  • Ventricular Tachycardia
  • Premature Ventricular Contraction